N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, provides an update on its patent application for Nuvec®, filed in November 2018 (no. PCT/GB2018/053298).
As announced on 15 November 2018, the Company filed a Patent Cooperation Treaty (“PCT”) patent application for improvements made to the manufacturing process for its Nuvec® system. Under the terms of the PCT application process and following conclusion of the national phasing, the Company is now required to make specific applications in the territories in which it wishes to gain patent protection.
In consideration of this, the Company is filing ongoing patent applications in the following territories: Europe (including the UK); USA; Japan; India; Australia; Canada; and China. These additional applications, if successful, claim priority from the Company’s United Kingdom patent application number 1718817.8.
Nigel Theobald, Chief Executive Officer of the Company, commented:
“We are seeking additional protection in the territories listed above, which the Board believes would provide maximum patent coverage for our PCT application whilst minimising outgoing expenditure. If the patents are granted in these regions, the Company will maintain its strong commercial protection of Nuvec ® .”
